We demonstrated that, in distinction to classical opioid receptors, ACKR3 won't bring about classical G protein signaling and is not modulated with the classical prescription or analgesic opioids, like morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists like naloxone. Instead, we proven that LIH383, an ACKR3-selective subnanomolar competitor https://busteru024ggf8.activablog.com/profile